| scholarly article | Q13442814 |
| P50 | author | Anjana Rao | Q85941651 |
| P2093 | author name string | Sakae Tanaka | |
| Katsuji Yoshioka | |||
| Jun-ichiro Inoue | |||
| Sakamuri V Reddy | |||
| Kenji Hata | |||
| Toshio Kukita | |||
| Toshiyuki Yoneda | |||
| Fumiyo Ikeda | |||
| Kenji Yamashita | |||
| Riko Nishimura | |||
| Takuma Matsubara | |||
| Toshiyuki Watanabe | |||
| Toru Hiraga | |||
| P2860 | cites work | JSAP1, a novel jun N-terminal protein kinase (JNK)-binding protein that functions as a Scaffold factor in the JNK signaling pathway | Q22010669 |
| Delta-opioid receptors expressed by Jurkat T cells enhance IL-2 secretion by increasing AP-1 complexes and activity of the NF-AT/AP-1-binding promoter element | Q24336669 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families | Q28137631 | ||
| Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice | Q28140546 | ||
| Bone resorption by osteoclasts | Q28145169 | ||
| NFAT signaling: choreographing the social lives of cells | Q28216151 | ||
| SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase | Q28364720 | ||
| TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling | Q28513445 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Plat-E: an efficient and stable system for transient packaging of retroviruses | Q29614830 | ||
| Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts | Q29618116 | ||
| Transcriptional regulation by calcium, calcineurin, and NFAT | Q29620410 | ||
| Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. | Q30778570 | ||
| Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome | Q33557797 | ||
| Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction | Q33886695 | ||
| Manipulating immune responses with immunosuppressive agents that target NFAT. | Q33906170 | ||
| Transcriptional mechanisms underlying lymphocyte tolerance. | Q34135663 | ||
| Partners in transcription: NFAT and AP-1. | Q34279371 | ||
| Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis | Q34764285 | ||
| Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice | Q35194925 | ||
| Requirement for NF-kappaB in osteoclast and B-cell development | Q35199657 | ||
| Life without white fat: a transgenic mouse | Q35210661 | ||
| Lack of a role for Jun kinase and AP-1 in Fas-induced apoptosis | Q36564701 | ||
| RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 | ||
| Characterization of the mouse tartrate-resistant acid phosphatase (trap) gene promoter | Q38297200 | ||
| Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator | Q38363724 | ||
| Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis | Q39714931 | ||
| Core-binding factor alpha 1 (Cbfa1) induces osteoblastic differentiation of C2C12 cells without interactions with Smad1 and Smad5. | Q40714066 | ||
| Smads, TAK1, and their common target ATF-2 play a critical role in cardiomyocyte differentiation. | Q40806167 | ||
| Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. | Q41069920 | ||
| RANK ligand-induced elevation of cytosolic Ca2+ accelerates nuclear translocation of nuclear factor kappa B in osteoclasts | Q42434967 | ||
| Regulation of the murine Nfatc1 gene by NFATc2. | Q42515564 | ||
| Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis | Q47761859 | ||
| Genetic control of skeletal development | Q58326890 | ||
| c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling | Q58326943 | ||
| A null mutation at the c-jun locus causes embryonic lethality and retarded cell growth in culture | Q62555340 | ||
| AP-1/jun is required for early Xenopus development and mediates mesoderm induction by fibroblast growth factor but not by activin | Q71070377 | ||
| The JNKK2-JNK1 fusion protein acts as a constitutively active c-Jun kinase that stimulates c-Jun transcription activity | Q73041131 | ||
| Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL) | Q73907464 | ||
| A JNK-Dependent Pathway Is Required for TNFα-Induced Apoptosis | Q79129693 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 475-484 | |
| P577 | publication date | 2004-08-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation | |
| P478 | volume | 114 |
| Q33634836 | (-)-Epicatechin 3-O-β-D-allopyranoside prevent ovariectomy-induced bone loss in mice by suppressing RANKL-induced NF-κB and NFATc-1 signaling pathways |
| Q35233222 | (5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway |
| Q24599024 | A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway |
| Q28535889 | Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production |
| Q34028709 | Activating transcription factor 4 regulates osteoclast differentiation in mice. |
| Q35953968 | Adenosine A1 receptor regulates osteoclast formation by altering TRAF6/TAK1 signaling. |
| Q35716436 | Adiponectin exacerbates collagen-induced arthritis via enhancing Th17 response and prompting RANKL expression |
| Q41003979 | Alexidine Dihydrochloride Attenuates Osteoclast Formation and Bone Resorption and Protects Against LPS-Induced Osteolysis |
| Q39028702 | Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling. |
| Q34968667 | Angelica sinensis extract inhibits RANKL-mediated osteoclastogenesis by down-regulated the expression of NFATc1 in mouse bone marrow cells |
| Q34529529 | Antibody to Receptor Activator of NF-κB Ligand Ameliorates T Cell-Mediated Periodontal Bone Resorption |
| Q90709611 | Asperpyrone A attenuates RANKL-induced osteoclast formation through inhibiting NFATc1, Ca2+ signalling and oxidative stress |
| Q64071625 | Association of Genetic Variants of , , and with Ankylosing Spondylitis Clinical Features in Taiwanese |
| Q37496714 | Attenuation of RANKL-induced Osteoclast Formation via p38-mediated NFATc1 Signaling Pathways by Extract of Euphorbia Lathyris L. |
| Q42972503 | Autoamplification of NFATc1 expression determines its essential role in bone homeostasis |
| Q37631691 | Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT. |
| Q46905561 | Beclin-1 is required for RANKL-induced osteoclast differentiation |
| Q36385024 | Blockade of JNK and NFAT pathways attenuates orthopedic particle-stimulated osteoclastogenesis of human osteoclast precursors and murine calvarial osteolysis |
| Q36466135 | Bone Morphogenetic Protein-2 (BMP-2) Activates NFATc1 Transcription Factor via an Autoregulatory Loop Involving Smad/Akt/Ca2+ Signaling |
| Q36245921 | CD44 deficiency inhibits unloading-induced cortical bone loss through downregulation of osteoclast activity |
| Q64236818 | Calcium-Phosphate Crystals Promote RANKL Expression via the Downregulation of DUSP1 |
| Q36404231 | Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-κB. |
| Q40214496 | Cardiovascular diseases and future risk of hip fracture in women |
| Q33882828 | Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL/M-CSF signaling and osteoclast polarization |
| Q34303394 | Characterization of functional reprogramming during osteoclast development using quantitative proteomics and mRNA profiling |
| Q37432210 | Complex regulation of tartrate-resistant acid phosphatase (TRAP) expression by interleukin 4 (IL-4): IL-4 indirectly suppresses receptor activator of NF-kappaB ligand (RANKL)-mediated TRAP expression but modestly induces its expression directly |
| Q40279586 | Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling |
| Q37038278 | Contributions to osteoclast biology from Japan |
| Q40238899 | Critical role of cortactin in actin ring formation and osteoclastic bone resorption. |
| Q47131626 | Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation |
| Q42426515 | Defective osteoclastogenesis by IKKbeta-null precursors is a result of receptor activator of NF-kappaB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation |
| Q30534461 | Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass |
| Q38293755 | Disruption of ZAS3 in mice alters NF-kappaB and AP-1 DNA binding and T-cell development. |
| Q92832466 | Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL-stimulated NFATc1 activity |
| Q47785875 | Dual roles of QOA-8a in antiosteoporosis: a combination of bone anabolic and anti-resorptive effects. |
| Q40120415 | Eriodictyol Inhibits RANKL-Induced Osteoclast Formation and Function Via Inhibition of NFATc1 Activity. |
| Q92453638 | Erythromyeloid progenitors give rise to a population of osteoclasts that contribute to bone homeostasis and repair |
| Q47941999 | Ethanol extract of Atractylodes macrocephala protects bone loss by inhibiting osteoclast differentiation. |
| Q51695975 | Expression characteristic and significance of interleukin-6, nuclear factor kappa beta, and bone formation markers in rat models of osteoporosis. |
| Q90412365 | Ferryl Hemoglobin Inhibits Osteoclastic Differentiation of Macrophages in Hemorrhaged Atherosclerotic Plaques |
| Q34691388 | Foxd3 suppresses NFAT-mediated differentiation to maintain self-renewal of embryonic stem cells |
| Q34486957 | Fucoidan, a sulfated polysaccharide, inhibits osteoclast differentiation and function by modulating RANKL signaling. |
| Q37453371 | Functional characterization of human osteoclast inhibitory peptide-1 (OIP-1/hSca) gene promoter |
| Q34170688 | Genetic Determinants of Osteoporosis: Common Bases to Cardiovascular Diseases? |
| Q47962107 | Glycyrrhizae Radix Inhibits Osteoclast Differentiation by Inhibiting c-Fos-Dependent NFATc1 Expression |
| Q39427988 | HDAC inhibitor trichostatin A suppresses osteoclastogenesis by upregulating the expression of C/EBP-β and MKP-1. |
| Q30354085 | Hearts and bones: shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development. |
| Q46982691 | High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells |
| Q64262538 | I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma |
| Q37342418 | IL-10 suppresses calcium-mediated costimulation of receptor activator NF-kappa B signaling during human osteoclast differentiation by inhibiting TREM-2 expression |
| Q38356185 | IL-12 stimulates the osteoclast inhibitory peptide-1 (OIP-1/hSca) gene expression in CD4+ T cells |
| Q53283430 | Identification and analysis of function of a novel splicing variant of mouse receptor activator of NF-κB. |
| Q39010754 | Identification of novel transcription factors in osteoclast differentiation using genome-wide analysis of open chromatin determined by DNase-seq |
| Q28511672 | Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals |
| Q41614826 | Immune system-related differentially expressed genes, transcription factors and microRNAs in post-menopausal females with osteopenia |
| Q36333546 | Inhibition of Osteoclastogenesis and Bone Resorption in vitro and in vivo by a prenylflavonoid xanthohumol from hops |
| Q42758736 | Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo. |
| Q34389834 | Inhibition of osteoclastogenesis by RNA interference targeting RANK. |
| Q28550685 | Inhibitory Effects of KP-A159, a Thiazolopyridine Derivative, on Osteoclast Differentiation, Function, and Inflammatory Bone Loss via Suppression of RANKL-Induced MAP Kinase Signaling Pathway |
| Q41864233 | Inhibitory effect of luteolin on osteoclast differentiation and function |
| Q48144315 | Inhibitory effect of sulphated polysaccharide porphyran (isolated from Porphyra yezoensis) on RANKL-induced differentiation of RAW264.7 cells into osteoclasts. |
| Q42077222 | Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice |
| Q46145950 | Inhibitory effects of eugenol on RANKL-induced osteoclast formation via attenuation of NF-κB and MAPK pathways |
| Q59356917 | Interferon-Gamma-Mediated Osteoimmunology |
| Q33269870 | Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus |
| Q36632162 | Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: a novel mechanism mediating its blockade of osteoclastogenesis |
| Q39018581 | Involvement of redox balance in in vitro osteoclast formation of RAW 264.7 macrophage cells in response to LPS. |
| Q90546441 | Isorhamnetin 3-O-neohesperidoside promotes the resorption of crown-covered bone during tooth eruption by osteoclastogenesis |
| Q57206333 | JNK/c-Jun Signaling Mediates an Anti-Apoptotic Effect of RANKL in Osteoclasts |
| Q59813634 | Jatrorrhizine Hydrochloride Suppresses RANKL-Induced Osteoclastogenesis and Protects against Wear Particle-Induced Osteolysis |
| Q64065423 | KBTBD11, a novel BTB-Kelch protein, is a negative regulator of osteoclastogenesis through controlling Cullin3-mediated ubiquitination of NFATc1 |
| Q47140180 | Kaempferide Prevents Titanium Particle Induced Osteolysis by Suppressing JNK Activation during Osteoclast Formation |
| Q37513913 | LIS1 Regulates Osteoclastogenesis through Modulation of M-SCF and RANKL Signaling Pathways and CDC42. |
| Q58008446 | Lipopolysaccharide suppresses RANK gene expression in macrophages by down-regulating PU.1 and MITF |
| Q38716121 | Lipoxin A4 suppresses osteoclastogenesis in RAW264.7 cells and prevents ovariectomy-induced bone loss |
| Q40145765 | Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades. |
| Q92000747 | Magnoflorine Suppresses MAPK and NF-κB Signaling to Prevent Inflammatory Osteolysis Induced by Titanium Particles In Vivo and Osteoclastogenesis via RANKL In Vitro |
| Q36749770 | Mechanisms of disease: Molecular insights into aseptic loosening of orthopedic implants |
| Q36073894 | Mechanistic insight into osteoclast differentiation in osteoimmunology |
| Q49503931 | Methionine-Restricted Diet Increases miRNAs That Can Target RUNX2 Expression and Alters Bone Structure in Young Mice |
| Q34240460 | Microarray-based gene expression profiling in patients with cryopyrin-associated periodic syndromes defines a disease-related signature and IL-1-responsive transcripts |
| Q38074961 | Molecular mechanisms of triggering, amplifying and targeting RANK signaling in osteoclasts |
| Q35084886 | Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB |
| Q28592329 | Molecules and signaling pathways involved in the expression of OC-STAMP during osteoclastogenesis |
| Q46371553 | N-(2-Hydroxyphenyl)acetamide: a Novel Suppressor of RANK/RANKL Pathway in Collagen-Induced Arthritis Model in Rats. |
| Q37448881 | NADPH oxidase gp91(phox) contributes to RANKL-induced osteoclast differentiation by upregulating NFATc1 |
| Q36725293 | NF-kappaB activation in development and progression of cancer |
| Q34912673 | NF-κB-direct activation of microRNAs with repressive effects on monocyte-specific genes is critical for osteoclast differentiation |
| Q41827067 | NFAT2 is an essential mediator of orthopedic particle-induced osteoclastogenesis |
| Q52018491 | NFATc1 expression in the developing heart valves is responsive to the RANKL pathway and is required for endocardial expression of cathepsin K. |
| Q34128188 | NIP45 negatively regulates RANK ligand induced osteoclast differentiation |
| Q28307600 | Negative autoregulation of RANKL and c-Src signaling in osteoclasts |
| Q92848007 | Nirogacestat suppresses RANKL-Induced osteoclast formation in vitro and attenuates LPS-Induced bone resorption in vivo |
| Q37399717 | Nitidine chloride prevents OVX-induced bone loss via suppressing NFATc1-mediated osteoclast differentiation |
| Q90232332 | Nuclear factor of activated T cells 2 is required for osteoclast differentiation and function in vitro but not in vivo |
| Q28817299 | OCLI-023, a Novel Pyrimidine Compound, Suppresses Osteoclastogenesis In Vitro and Alveolar Bone Resorption In Vivo |
| Q52564590 | Optimized Extract from Corylopsis coreana Uyeki (Hamamelidaceae) Flos Inhibits Osteoclast Differentiation. |
| Q50959261 | Osteoblast-derived Laminin-332 is a novel negative regulator of osteoclastogenesis in bone microenvironments. |
| Q46960866 | Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-kappaB transactivation by RANKL. |
| Q37435119 | Osteoclast inhibitory peptide-1 (OIP-1) inhibits measles virus nucleocapsid protein stimulated osteoclast formation/activity |
| Q33925042 | Osteoclast motility: putting the brakes on bone resorption. |
| Q36324916 | Osteoclast precursors, RANKL/RANK, and immunology |
| Q79370827 | Osteoclastic differentiation and function regulated by old and new pathways |
| Q37808649 | Osteoclastogenesis and arthritis |
| Q24683898 | Osteoclasts: what do they do and how do they do it? |
| Q34896003 | Osteoclasts; culprits in inflammatory osteolysis |
| Q47944184 | Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems. |
| Q38960189 | Osteoimmunology: memorandum for rheumatologists. |
| Q39804721 | Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling |
| Q36105975 | PIAS3 negatively regulates RANKL-mediated osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblasts. |
| Q38744013 | PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. |
| Q92876675 | PP121 suppresses RANKL-Induced osteoclast formation in vitro and LPS-Induced bone resorption in vivo |
| Q58699564 | PRMT1 mediates RANKL-induced osteoclastogenesis and contributes to bone loss in ovariectomized mice |
| Q49831611 | Paeoniflorin Inhibits Receptor Activator for Nuclear Factor κB (RANK) Ligand-Induced Osteoclast Differentiation In Vitro and Particle-Induced Osteolysis In Vivo |
| Q55344415 | Paeoniflorin regulates osteoclastogenesis and osteoblastogenesis via manipulating NF-κB signaling pathway both in vitro and in vivo. |
| Q33357359 | Paraspeckle protein p54nrb links Sox9-mediated transcription with RNA processing during chondrogenesis in mice |
| Q38835344 | Pasteurella multocida toxin- induced osteoclastogenesis requires mTOR activation |
| Q53698184 | Poligoni Multiflori Radix enhances osteoblast formation and reduces osteoclast differentiation. |
| Q43503691 | Positive regulation of osteogenesis by bile acid through FXR. |
| Q35617594 | Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis |
| Q47632345 | Potential role of rebamipide in osteoclast differentiation and mandibular condylar cartilage homeostasis |
| Q24812326 | Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. |
| Q38911203 | Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways |
| Q38307924 | RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation |
| Q41107411 | RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. |
| Q37286493 | RANKing c-Jun in osteoclast development |
| Q35800463 | RNA therapeutics targeting osteoclast-mediated excessive bone resorption |
| Q40365350 | Regulation of osteoclastogenesis by Simon extracts composed of caffeic acid and related compounds: successful suppression of bone destruction accompanied with adjuvant-induced arthritis in rats |
| Q35347883 | Role of NF-κB in the skeleton |
| Q36324929 | Role of nuclear factor-kappaB in the immune system and bone |
| Q36177501 | Roles for NF-kappaB and c-Fos in osteoclasts |
| Q39817003 | Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts |
| Q36082866 | Signaling networks that control the lineage commitment and differentiation of bone cells |
| Q28587852 | Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formation |
| Q39957832 | Stimulation of macrophage TNFalpha production by orthopaedic wear particles requires activation of the ERK1/2/Egr-1 and NF-kappaB pathways but is independent of p38 and JNK. |
| Q36847530 | Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model |
| Q50896849 | Systems level analysis of osteoclastogenesis reveals intrinsic and extrinsic regulatory interactions. |
| Q48088552 | TNF-α promotes osteoclastogenesis through JNK signaling-dependent induction of Semaphorin3D expression in estrogen-deficiency induced osteoporosis. |
| Q83061700 | Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis |
| Q46592953 | Thapsigargin modulates osteoclastogenesis through the regulation of RANKL-induced signaling pathways and reactive oxygen species production. |
| Q53542645 | The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling. |
| Q92664754 | The IRF2BP2-KLF2 axis regulates osteoclast and osteoblast differentiation |
| Q28512132 | The LIM protein, Limd1, regulates AP-1 activation through an interaction with Traf6 to influence osteoclast development |
| Q41928709 | The R740S mutation in the V-ATPase a3 subunit increases lysosomal pH, impairs NFATc1 translocation, and decreases in vitro osteoclastogenesis. |
| Q47381565 | The actin-binding protein PPP1r18 regulates maturation, actin organization, and bone resorption activity of osteoclasts. |
| Q28508398 | The association of Notch2 and NF-kappaB accelerates RANKL-induced osteoclastogenesis |
| Q38669228 | The effects of tumour necrosis factor-α on bone cells involved in periodontal alveolar bone loss; osteoclasts, osteoblasts and osteocytes. |
| Q41683326 | The inhibitors of cyclin-dependent kinases and GSK-3β enhance osteoclastogenesis |
| Q33842055 | The large zinc finger protein ZAS3 is a critical modulator of osteoclastogenesis |
| Q35831159 | The regulation of osteoclast differentiation by Wnt signals |
| Q37969065 | The role of T-cell leukemia translocation-associated gene protein in human tumorigenesis and osteoclastogenesis |
| Q34152121 | The study of mechanisms of protective effect of Rg1 against arthritis by inhibiting osteoclast differentiation and maturation in CIA mice |
| Q55117611 | Therapeutic and Preventive Effects of Osteoclastogenesis Inhibitory Factor on Osteolysis, Proliferation of Mammary Tumor Cell and Induction of Cancer Stem Cells in the Bone Microenvironment. |
| Q28485361 | Transcriptional regulation of VEGFA by the endoplasmic reticulum stress transducer OASIS in ARPE-19 cells |
| Q90593268 | Transcriptomic Data Identified Key Transcription Factors for Osteoporosis in Caucasian Women |
| Q37453357 | Transgenic mice with OIP-1/hSca overexpression targeted to the osteoclast lineage develop an osteopetrosis bone phenotype |
| Q34505005 | Two heterozygous mutations in NFATC1 in a patient with Tricuspid Atresia. |
| Q100565852 | USF3 modulates osteoporosis risk by targeting WNT16, RANKL, RUNX2 and two GWAS lead SNPs rs2908007 and rs4531631 |
| Q37694304 | Update on Targets of Biologic Therapies for Rheumatoid Arthritis. |
| Q36900096 | Water Extract of Dryopteris crassirhizoma Attenuates Bone Loss by Suppressing Osteoclast Differentiation and Function |
| Q57223100 | Water extract of Acer tegmentosum reduces bone destruction by inhibiting osteoclast differentiation and function |
| Q53221570 | Water extract of Magnolia officinalis cortex inhibits osteoclastogenesis and bone resorption by downregulation of nuclear factor of activated T cells cytoplasmic 1. |
| Q34732774 | Water extract of Spatholobus suberectus inhibits osteoclast differentiation and bone resorption |
| Q52737480 | Water extract of Uncaria sinensis suppresses RANKL-induced bone loss by attenuating osteoclast differentiation and bone resorption. |
| Q34278522 | Water extract of the fruits of Alpinia oxyphylla inhibits osteoclast differentiation and bone loss |
| Q41952301 | Wogonin inhibits osteoclast differentiation by inhibiting NFATc1 translocation into the nucleus |
| Q92581791 | Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways |
Search more.